

Quality Measure Reports

Accountability Measure

- Considered the current standard of care based on clinical trial evidence Commission on Cancer Standard 4.4.

Quality Improvement Measure (QI)

- Demonstrates good practice based on consensus. Usually not based on clinical trial evidence. Commission on Cancer Standard 4.5 addresses compliance with quality improvement.



Cancer Program Practice Profile (CP³R) Estimated Performance Rates

- Breast (6)
- Colon (2)
- Non-Small Cell Lung (2)
- Gastric (1)

Extensive assessment and validation of the measures were performed using cancer registry data reported to the National Cancer Data Base (NCDB).

Disclaimer: All measures are designed to assess performance at the hospital or systems-level, and are not intended for application to individual physician performance.


Quality Measure Reports – Breast

- **BCSRT:** Breast radiation after breast conserving surgery (NQF 0219 – Accountability Measure)
- **MAC:** Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 – Accountability Measure)
- **HT:** Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 – Accountability Measure)
- **BCS:** Breast conserving surgery rate (Surveillance Measure)
- **MASRT:** Radiation therapy considered or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes (Accountability Measure)
- **nBx:** Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement Measure)

NQF = National Quality Forum Endorsed Measure




BREAST, 2012, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	91.2 %	96.6 %	93.2 %	96.1 %	90.8 %	90.3 %

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 12/12/2014)


BREAST, 2012, MAC: Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 - Accountability Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	98.7 %	93.5 %	96.3 %	92 %	90.8 %

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 12/12/2014)


BREAST, 2012, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	97.3 %	91.4 %	95.4 %	88.3 %	87.7 %

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 12/12/2014)


BREAST, 2012, MASRT: Radiation therapy considered or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	97.6 %	88.5 %	94.6 %	84.9 %	84.5 %

Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. (CP3R data as of 12/12/2014)

BREAST, 2012, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	95.9 %	92.6 %	87.7 %	90.7 %	87.7 %	87.6 %

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 12/12/2014)


Quality Measure Reports - Colon

- **ACT:** Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 – Accountability Measure)
- **12RL:** At least 12 lymph nodes are removed and examined as part of primary colon cancer resection (NQF 0225 – Quality Improvement Measure)

NQF = National Quality Forum Endorsed Measure



COLON, 2012, ACT: Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 - Accountability Measure)




	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	87.5 %	95.3 %	91.3 %	95.1 %	87.7 %	86.4 %

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 12/12/2014)



COLON, 2012, 12RL: At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer (NQF 0225 - Quality Improvement Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	93.2 %	89.2 %	90.9 %	87.8 %	88.1 %


At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 12/12/2014)

Quality Measure Reports - Non-Small Cell Lung

- **10RLN:** At least 10 regional lymph nodes removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC (Surveillance Measure)
- **LT:** Systemic chemotherapy is administered or considered within 4 months prior to surgery or within 6 months postoperatively for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement Measure)



NSCLC, 2012, LCT: Systemic chemotherapy administered or considered 4 months prior surgery or 6 months postoperatively resected cases with pN1 or pN2 (Quality Improvement Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	96.7 %	89.9 %	92.4 %	83.8 %	84.7 %


Systemic chemotherapy administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node-positive (pN1) or (pN2) NSCLC.(CP3R data as of 12/12/2014)

Quality Measure Reports - Gastric

- **G15RLN:** At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement Measure)



Gastric, 2012, G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement Measure)



	My Program	My State (WI)	My Census Region (East North Central)	My ACS Division (MidWest)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	NA	48.6 %	54.2 %	56.4 %	45.7 %	52.7 %

At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. (CP3R data as of 12/12/2014)